Ascletis Pharma (HKSE:01672) Price-to-Tangible-Book : 0.47 (As of Jun. 05, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Price-to-Tangible-Book?

As of today (2024-06-05), Ascletis Pharma's share price is HK$1.14. Ascletis Pharma's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$2.43. Hence, Ascletis Pharma's Price to Tangible Book Ratio of today is 0.47.

The historical rank and industry rank for Ascletis Pharma's Price-to-Tangible-Book or its related term are showing as below:

HKSE:01672' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.46 Med: 1.02 Max: 1.87
Current: 0.47

During the past 8 years, Ascletis Pharma's highest Price to Tangible Book Ratio was 1.87. The lowest was 0.46. And the median was 1.02.

HKSE:01672's Price-to-Tangible-Book is ranked better than
95.5% of 1221 companies
in the Biotechnology industry
Industry Median: 2.78 vs HKSE:01672: 0.47

A closely related ratio is called PB Ratio. As of today, Ascletis Pharma's share price is HK$1.14. Ascletis Pharma's Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$2.46. Hence, Ascletis Pharma's P/B Ratio of today is 0.46.

Ascletis Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Ascletis Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Price-to-Tangible-Book Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

0.91

0.92

1.11

1.83

0.60

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial										1.11	1.33	1.83	0.73	0.60

Competitive Comparison of Ascletis Pharma's Price-to-Tangible-Book

For the Biotechnology subindustry, Ascletis Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Price-to-Tangible-Book falls into.

Ascletis Pharma Price-to-Tangible-Book Calculation

Ascletis Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	1.14	/	2.429
	=	0.47

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Ascletis Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma (HKSE:01672) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

ASCLF:USA

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.

Executives

Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma (HKSE:01672) Headlines

No Headlines